Wiaam Al Hasani, Christopher N Floyd, Cheryl Walsh, Shu C Michael Yau, Soundrie T Padayachee, Zofia McMahon, Radha Ramachandran, Martin A Crook, Anthony S Wierzbicki
{"title":"心血管和影像学生物标志物识别家族性高胆固醇血症患者指标的诊断准确性","authors":"Wiaam Al Hasani, Christopher N Floyd, Cheryl Walsh, Shu C Michael Yau, Soundrie T Padayachee, Zofia McMahon, Radha Ramachandran, Martin A Crook, Anthony S Wierzbicki","doi":"10.1080/03007995.2025.2536607","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the utility of secondary stratification measures in ascertainment of index cases for monogenic familial hypercholesterolaemia (FH).</p><p><strong>Methods: </strong>Referrals from primary care were screened by methods for the potential diagnosis of FH, including Simon Broome (SB) or Dutch Lipid Clinic Network score (DLCN) criteria, initial LDL-C, lipoprotein (a) (Lp(a)) > 125 nM, troponin-T (hsTnT), imaging using carotid intima-media thickness and plaque assessment and a single nucleotide polymorphism (SNP) polygenic hypercholesterolaemia panel (12 loci).</p><p><strong>Results: </strong>The population comprised 793 patients aged 55 ± 17 years, of whom 3% had tendon xanthomata, 7% coronary artery disease, and with pre-treatment LDL-C 5.84 ± 1.47 mmol/L. Genotyping was performed in 793 patients and 36% had monogenic FH. Dutch lipid score assessment was associated with a positive likelihood ratio (PLR) for FH 3.91 with a net reclassification index (NRI) of 8% while addition of negative modification for triglycerides (Welsh lipid score) had a PLR 6.88 (NRI 30%). In the whole cohort, the SNP12 score had a negative LR (NLR) of 1.32 (NRI -16%) above the 75<sup>th</sup> centile while Lp(a) > 125nmol/L had a NLR of 1.18 (NRI -29%) and raised hsTnT a PLR of 1.08 (NRI -16%). In a non-pre-stratified primary care cohort (<i>n</i> = 236), imaging had a PLR 1.70 (NRI 14%) for identifying patients with FH.</p><p><strong>Conclusions: </strong>A clinical algorithm based on Welsh Lipid score criteria modifying DLCN score for triglycerides allied with stratification for the presence of tendon xanthomata, highly elevated LDL-C (>7 mmol/L) or positive imaging provides an efficient system to raise the yield of diagnosis of FH with a low chance of missing cases.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1173-1183"},"PeriodicalIF":2.2000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diagnostic accuracy of cardiovascular and imaging biomarkers to identify index patients with familial hypercholesterolaemia.\",\"authors\":\"Wiaam Al Hasani, Christopher N Floyd, Cheryl Walsh, Shu C Michael Yau, Soundrie T Padayachee, Zofia McMahon, Radha Ramachandran, Martin A Crook, Anthony S Wierzbicki\",\"doi\":\"10.1080/03007995.2025.2536607\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To determine the utility of secondary stratification measures in ascertainment of index cases for monogenic familial hypercholesterolaemia (FH).</p><p><strong>Methods: </strong>Referrals from primary care were screened by methods for the potential diagnosis of FH, including Simon Broome (SB) or Dutch Lipid Clinic Network score (DLCN) criteria, initial LDL-C, lipoprotein (a) (Lp(a)) > 125 nM, troponin-T (hsTnT), imaging using carotid intima-media thickness and plaque assessment and a single nucleotide polymorphism (SNP) polygenic hypercholesterolaemia panel (12 loci).</p><p><strong>Results: </strong>The population comprised 793 patients aged 55 ± 17 years, of whom 3% had tendon xanthomata, 7% coronary artery disease, and with pre-treatment LDL-C 5.84 ± 1.47 mmol/L. Genotyping was performed in 793 patients and 36% had monogenic FH. Dutch lipid score assessment was associated with a positive likelihood ratio (PLR) for FH 3.91 with a net reclassification index (NRI) of 8% while addition of negative modification for triglycerides (Welsh lipid score) had a PLR 6.88 (NRI 30%). In the whole cohort, the SNP12 score had a negative LR (NLR) of 1.32 (NRI -16%) above the 75<sup>th</sup> centile while Lp(a) > 125nmol/L had a NLR of 1.18 (NRI -29%) and raised hsTnT a PLR of 1.08 (NRI -16%). In a non-pre-stratified primary care cohort (<i>n</i> = 236), imaging had a PLR 1.70 (NRI 14%) for identifying patients with FH.</p><p><strong>Conclusions: </strong>A clinical algorithm based on Welsh Lipid score criteria modifying DLCN score for triglycerides allied with stratification for the presence of tendon xanthomata, highly elevated LDL-C (>7 mmol/L) or positive imaging provides an efficient system to raise the yield of diagnosis of FH with a low chance of missing cases.</p>\",\"PeriodicalId\":10814,\"journal\":{\"name\":\"Current Medical Research and Opinion\",\"volume\":\" \",\"pages\":\"1173-1183\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Medical Research and Opinion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/03007995.2025.2536607\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2536607","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Diagnostic accuracy of cardiovascular and imaging biomarkers to identify index patients with familial hypercholesterolaemia.
Objective: To determine the utility of secondary stratification measures in ascertainment of index cases for monogenic familial hypercholesterolaemia (FH).
Methods: Referrals from primary care were screened by methods for the potential diagnosis of FH, including Simon Broome (SB) or Dutch Lipid Clinic Network score (DLCN) criteria, initial LDL-C, lipoprotein (a) (Lp(a)) > 125 nM, troponin-T (hsTnT), imaging using carotid intima-media thickness and plaque assessment and a single nucleotide polymorphism (SNP) polygenic hypercholesterolaemia panel (12 loci).
Results: The population comprised 793 patients aged 55 ± 17 years, of whom 3% had tendon xanthomata, 7% coronary artery disease, and with pre-treatment LDL-C 5.84 ± 1.47 mmol/L. Genotyping was performed in 793 patients and 36% had monogenic FH. Dutch lipid score assessment was associated with a positive likelihood ratio (PLR) for FH 3.91 with a net reclassification index (NRI) of 8% while addition of negative modification for triglycerides (Welsh lipid score) had a PLR 6.88 (NRI 30%). In the whole cohort, the SNP12 score had a negative LR (NLR) of 1.32 (NRI -16%) above the 75th centile while Lp(a) > 125nmol/L had a NLR of 1.18 (NRI -29%) and raised hsTnT a PLR of 1.08 (NRI -16%). In a non-pre-stratified primary care cohort (n = 236), imaging had a PLR 1.70 (NRI 14%) for identifying patients with FH.
Conclusions: A clinical algorithm based on Welsh Lipid score criteria modifying DLCN score for triglycerides allied with stratification for the presence of tendon xanthomata, highly elevated LDL-C (>7 mmol/L) or positive imaging provides an efficient system to raise the yield of diagnosis of FH with a low chance of missing cases.
期刊介绍:
Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance